According to Zacks, "CRISPR Therapeutics AG is a gene-editing company". SunTrust Banks also issued estimates for Crispr Therapeutics' FY2019 earnings at ($3.22) EPS, FY2020 earnings at ($3.79) EPS, FY2021 earnings at ($3.81) EPS and FY2022 earnings at ($3.83) EPS.
Analysts expect CRISPR Therapeutics AG (NASDAQ:CRSP) to report $-0.74 EPS on March, 9.They anticipate $0.34 EPS change or 85.00% from last quarter's $-0.4 EPS. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. After $-0.07 actual earnings per share reported by CUI Global, Inc. for the previous quarter, Wall Street now forecasts -14.29% EPS growth. The company had revenue of $2.39 million during the quarter, compared to analysts' expectations of $3.61 million. During the same quarter last year, the business earned ($2.77) earnings per share. equities research analysts expect that Crispr Therapeutics will post -2.42 EPS for the current year. The business's revenue was up 54.2% on a year-over-year basis.
Among 5 analysts covering CRISPR Therapeutics (NASDAQ:CRSP), 4 have Buy rating, 0 Sell and 1 Hold. BidaskClub upgraded shares of Crispr Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, January 4th. Finally, Oppenheimer started coverage on shares of Crispr Therapeutics in a research report on Thursday, December 7th. Piper Jaffray Companies reissued a "buy" rating and issued a $22.75 price objective (down from $39.00) on shares of Crispr Therapeutics in a research report on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. The stock now has an average rating of "Buy" and an average target price of $22.81.
COPYRIGHT VIOLATION WARNING: "Zacks Investment Research Downgrades Crispr Therapeutics (CRSP) to Sell" was published by StockNewsTimes and is the property of of StockNewsTimes. The stock had a trading volume of 748,954 shares, compared to its average volume of 929,765.
A number of hedge funds and other institutional investors have recently modified their holdings of CRSP. Crispr Therapeutics has a 1 year low of $11.63 and a 1 year high of $45.00. The firm has a market capitalization of $1,600.00 and a price-to-earnings ratio of -109.00.
In related news, Director Thomas Woiwode sold 1,700 shares of Crispr Therapeutics stock in a transaction that occurred on Friday, November 24th. The shares were purchased at an average cost of $22.75 per share, for a total transaction of $11,999,988.00. The stock was sold at an average price of $18.98, for a total value of $21,114,225.08. Following the completion of the sale, the director now owns 8,218 shares of the company's stock, valued at $166,085.78. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Tyler Dylan-Hyde sold 66,000 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, January 16th. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,105,543 shares of company stock worth $41,977,806. Wells Fargo & Company MN lifted its position in shares of Crispr Therapeutics by 459.7% during the second quarter. Opaleye Management Inc. bought a new stake in shares of Crispr Therapeutics during the fourth quarter worth $6,597,000. Capital Investment Advisory Services LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth about $193,000. Moloney Securities Asset Management LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth about $235,000. BlackRock Inc. now owns 552,558 shares of the company's stock worth $12,974,000 after buying an additional 549,254 shares during the last quarter. If you are accessing this report on another site, it was stolen and republished in violation of United States & global copyright & trademark law.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 gene-editing platform in Switzerland.